| Funding Opportunity ID: |
313362 |
| Opportunity Number: |
W81XWH-19-OCRP-CDA |
| Opportunity Title: |
DoD Ovarian Cancer Clinical Development Award |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement
Grant |
| Category of Funding Activity: |
Science and Technology and other Research and Development |
| Category Explanation: |
|
| CFDA Number(s): |
12.420 |
| Eligible Applicants: |
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
| Additional Information on Eligibility: |
|
| Agency Code: |
DOD-AMRAA |
| Agency Name: |
Department of Defense
Dept. of the Army -- USAMRAA |
| Posted Date: |
Mar 01, 2019 |
| Close Date: |
Jul 31, 2019 |
| Last Updated Date: |
Mar 01, 2019 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
$4,480,000 |
| Expected Number of Awards: |
4 |
| Description: |
The OCRP Clinical Development Award is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life. The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Proof of concept demonstrating the potential utility of the proposed product or a prototype/ preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required. |
| Version: |
1 |
|
Published at: March 01, 2019 at 09:15PM
View on Grants.gov
No comments:
Post a Comment